Brokerages Set Coherus Biosciences Inc (CHRS) Target Price at $32.00

Coherus Biosciences Inc (NASDAQ:CHRS) has earned an average rating of “Hold” from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $32.00.

CHRS has been the topic of a number of recent analyst reports. J P Morgan Chase & Co reissued an “overweight” rating and issued a $25.00 price objective (down from $32.00) on shares of Coherus Biosciences in a research note on Tuesday, August 8th. Credit Suisse Group reissued an “outperform” rating and issued a $17.00 price objective (down from $24.00) on shares of Coherus Biosciences in a research note on Wednesday, September 27th. ValuEngine raised Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Maxim Group reissued a “buy” rating and issued a $20.00 price objective (down from $40.00) on shares of Coherus Biosciences in a research note on Friday, September 8th. Finally, Cowen reissued an “outperform” rating and issued a $45.00 price objective on shares of Coherus Biosciences in a research note on Friday, September 8th.

Coherus Biosciences (NASDAQ CHRS) traded up $0.10 during trading hours on Friday, reaching $8.90. The company had a trading volume of 369,026 shares, compared to its average volume of 600,417. The company has a current ratio of 5.46, a quick ratio of 5.46 and a debt-to-equity ratio of 1.84. Coherus Biosciences has a 1 year low of $8.05 and a 1 year high of $29.59.

Coherus Biosciences (NASDAQ:CHRS) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. sell-side analysts anticipate that Coherus Biosciences will post -4.39 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Ladenburg Thalmann Financial Services Inc. increased its position in Coherus Biosciences by 497.4% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock worth $168,000 after buying an additional 10,491 shares during the period. Platinum Investment Management Ltd. bought a new position in Coherus Biosciences in the 3rd quarter worth approximately $1,457,000. Temasek Holdings Private Ltd bought a new position in Coherus Biosciences in the 3rd quarter worth approximately $87,524,000. Brown Advisory Inc. increased its position in Coherus Biosciences by 5.5% in the 3rd quarter. Brown Advisory Inc. now owns 594,021 shares of the biotechnology company’s stock worth $7,930,000 after buying an additional 31,211 shares during the period. Finally, Wells Fargo & Company MN increased its position in Coherus Biosciences by 429.0% in the 3rd quarter. Wells Fargo & Company MN now owns 154,026 shares of the biotechnology company’s stock worth $2,056,000 after buying an additional 124,910 shares during the period. 81.07% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Coherus Biosciences Inc (CHRS) Target Price at $32.00” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/04/brokerages-set-coherus-biosciences-inc-chrs-target-price-at-32-00.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

What are top analysts saying about Coherus Biosciences Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Coherus Biosciences Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit